Lemtrada

Pharma

NICE gives a thumbs-down to Bristol Myers' MS newcomer Zeposia

NICE said it struggled to see how the benefits of Zeposia justify its cost, citing a lack of data comparing it to rival MS drugs like Roche’s Ocrevus.

Arlene Weintraub Jan 22, 2021 11:21am

Sanofi ponies up $315M to settle Lemtrada milestone spat

Nov 4, 2019 10:30am

Sanofi's Lemtrada goes under EU review for fatal side effects

Apr 15, 2019 11:35am

Merck KGaA finally chalks up FDA nod for MS med Mavenclad

Apr 1, 2019 10:20am

FDA hits Sanofi's struggling Lemtrada with new safety warning

Nov 30, 2018 10:48am

Can Sanofi's new long-term Lemtrada data amp up MS sales?

Oct 11, 2018 9:59am